Rhythm Pharmaceuticals
RYTM
88.45
-2.32
-2.56%
Rhythm Pharmaceuticals
US · RYTM
#1874 by market cap
Listed 2017
88.45
-2.32
-2.56%
Live - 5344 symbols - heartbeat 415s ago
· 2026-10-08 08:06
Pre-market
87.90
-0.62%
After-hours
88.45
0.00%
Overnight
88.34
-0.12%
- Market cap
- 6.09B
- P/E (TTM)i
- -28.35
- P/Bi
- 59.12
- EPSi
- -3.11
- Div yieldi
- 0.00%
- 52W posi
- 29%
Reader sentiment
Are you bullish or bearish on RYTM?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 14 analysts
Buy
Avg price target
143.50 +62.2%
Price target rangecurrent 88.45
Low120.00
Avg143.50
High160.00
Buy 93%
Hold 7%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-17 | Wolfe Research | -- | BUY | -- |
| 2026-09-15 | J.P. Morgan | -- | BUY | -- |
| 2026-09-14 | Leerink Partners | -- | BUY | 133.00 |
| 2026-09-14 | RBC Capital | -- | BUY | 155.00 |
| 2026-08-27 | Deutsche Bank | -- | HOLD | 120.00 |
| 2026-08-24 | Morgan Stanley | -- | BUY | 150.00 |
| 2026-08-24 | Guggenheim | -- | BUY | 143.00 |
| 2026-08-10 | J.P. Morgan | -- | BUY | 146.00 |
| 2026-08-05 | CCORF | -- | BUY | 154.00 |
| 2026-08-05 | Citizens JMP | -- | BUY | 160.00 |
| 2026-08-05 | Morgan Stanley | -- | BUY | 150.00 |
| 2026-08-05 | Citi | -- | BUY | 143.00 |
| 2026-08-04 | TD Cowen | -- | BUY | 130.00 |
| 2026-08-04 | BofA Securities | -- | BUY | 149.00 |
| 2026-08-04 | Needham | -- | BUY | 130.00 |
| 2026-08-04 | Guggenheim | -- | BUY | 143.00 |
| 2026-08-04 | RBC Capital | -- | BUY | 155.00 |
| 2026-07-16 | Wells Fargo | -- | BUY | 155.00 |
| 2026-07-15 | BofA Securities | -- | BUY | -- |
| 2026-07-07 | CCORF | -- | BUY | 151.00 |
| 2026-07-07 | RBC Capital | -- | BUY | 141.00 |
| 2026-06-17 | TD Cowen | -- | BUY | 130.00 |
| 2026-06-17 | Wells Fargo | -- | BUY | 155.00 |
| 2026-06-16 | CCORF | -- | BUY | 151.00 |
| 2026-06-15 | Wells Fargo | -- | BUY | 155.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Sell
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | -- | ±11.25% | +2.92% (in line) |
| 2026/Q1 | 2026-05-05 | -- | ±11.16% | +7.86% (in line) |
| 2025/Q4 | 2026-02-26 | -- | ±14.17% | -1.09% (in line) |
| 2025/Q3 | 2025-11-04 | -- | ±9.68% | -7.69% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±9.45% | -1.85% (in line) |
| 2025/Q1 | 2025-05-07 | -- | ±12.54% | +3.06% (in line) |
| 2024/Q4 | 2025-02-26 | -- | ±10.15% | +4.49% (in line) |
| 2024/Q3 | 2024-11-05 | After close | ±8.36% | +11.38% (beat) |
| 2024/Q2 | 2024-08-06 | -- | ±25.32% | +0.02% (in line) |
| 2024/Q1 | 2024-05-07 | -- | ±8.75% | -10.32% (beat) |
| 2023/Q4 | 2024-02-22 | -- | ±15.48% | -9.73% (in line) |
| 2023/Q3 | 2023-11-07 | -- | ±11.85% | -0.52% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 08:06:05 · For reference only, not investment advice and not tailored to your situation.